BUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT

Reuters

Feb 24, 2025

** U.S. drug developer Amneal Pharmaceuticals AMRX.O rises 4.09% to $8.15 in premarket trading

** J.P.Morgan upgrades to "overweight" from "neutral"; lifts PT from $9 to $12, ~42% upside to last close of $7.83

** Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars

** Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's (co's independent subsidiary) impressive growth

** Stock rated "buy" on avg; median PT is $11 - LSEG

** AMRX down 1.13% so far this year, as of Friday's close

(Reporting by Rashika Singh in Bengaluru)

((rashika.singh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2513484277"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513484277\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2513484277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513484277","market":"us","top_or_hot":-1,"title":"BUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT</title></head><body><p>** U.S. drug developer Amneal Pharmaceuticals <span>AMRX.O</span> rises 4.09% to $8.15 in premarket trading</p><p>** J.P.Morgan upgrades to \"overweight\" from \"neutral\"; lifts PT from $9 to $12, ~42% upside to last close of $7.83</p><p>** Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars</p><p>** Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's (co's independent subsidiary) impressive growth</p><p>** Stock rated \"buy\" on avg; median PT is $11 - LSEG</p><p>** AMRX down 1.13% so far this year, as of Friday's close</p><p> (Reporting by Rashika Singh in Bengaluru)</p><p> ((rashika.singh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-24 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT</title></head><body><p>** U.S. drug developer Amneal Pharmaceuticals <span>AMRX.O</span> rises 4.09% to $8.15 in premarket trading</p><p>** J.P.Morgan upgrades to \"overweight\" from \"neutral\"; lifts PT from $9 to $12, ~42% upside to last close of $7.83</p><p>** Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars</p><p>** Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's (co's independent subsidiary) impressive growth</p><p>** Stock rated \"buy\" on avg; median PT is $11 - LSEG</p><p>** AMRX down 1.13% so far this year, as of Friday's close</p><p> (Reporting by Rashika Singh in Bengaluru)</p><p> ((rashika.singh@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3N3PF0EC:1","article_id":"2513484277","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513484277","pubTimestamp":1740389657,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT** U.S. drug developer Amneal Pharmaceuticals AMRX.O rises 4.09% to $8.15 in premarket trading** J.P.Morgan upgrades to \"overweight\" from \"neutral\"; lifts PT from $9 to $12, ~42% upside to last close of $7.83** Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars** Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's  impressive growth** Stock rated \"buy\" on avg; median PT is $11 - LSEG** AMRX down 1.13% so far this year, as of Friday's close  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"嗡嗡声——Amneal Pharma上涨；摩根大通上调股票评级并提高PT","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":0.9},"content_text":"BUZZ-Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT** U.S. drug developer Amneal Pharmaceuticals AMRX.O rises 4.09% to $8.15 in premarket trading** J.P.Morgan upgrades to \"overweight\" from \"neutral\"; lifts PT from $9 to $12, ~42% upside to last close of $7.83** Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars** Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's (co's independent subsidiary) impressive growth** Stock rated \"buy\" on avg; median PT is $11 - LSEG** AMRX down 1.13% so far this year, as of Friday's close (Reporting by Rashika Singh in Bengaluru) ((rashika.singh@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}